Status:
UNKNOWN
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
Lead Sponsor:
Baqiyatallah Medical Sciences University
Conditions:
COVID-19
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among...
Eligibility Criteria
Inclusion
- Conscious consent to participate in the study
- Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR.
- Strong clinical suspicion of covid 19 with positive findings in CT Scan
- Shortness of breath
Exclusion
- Patients with HIV
- Patients with cancer undergoing chemotherapy
- Patients receiving Immune Mediators
- Patients need hospitalization in the intensive care unit
- Patients with uncontrolled heart, kidney or liver failure
- Pregnant or lactating women
- Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)
Key Trial Info
Start Date :
August 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2020
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04463420
Start Date
August 15 2020
End Date
December 15 2020
Last Update
November 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohammad Sadegh Bagheri Baghdasht
Tehran, Iran, 0